Endothelin in chronic heart failure: Current position and future prospects

Cardiovascular Research

Volumn 31, Issue 5, 1996, Pages 655-674

  Love, Michael P ^a   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Endothelin receptor; Endothelin 1; Heart failure

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

HEART FAILURE; HUMAN; PRIORITY JOURNAL; REVIEW;

ASPARTIC ENDOPEPTIDASES; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; METALLOENDOPEPTIDASES; RECEPTORS, ENDOTHELIN;

EID: 0029971982     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00055-7     Document Type: Review

References (99)

1. Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. Br Med J 1994;308:321-28.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-57.
3. Hood WB. Role of converting enzyme inhibitors in the treatment of heart failure. J Am Coll Cardiol 1993;22(Suppl A):154-57A.
4. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993;6:91-98.
5. Kannel WB, Ho K, Thorn T. Changing epidemiological features of cardiac failure. Br Heart J (Suppl No 2) 1994;72:S3-9.
6. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Conn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-77.
7. Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
8. Zelis R, Longhurst J, Capone RJ, Mason DT. A comparison of regional blood flow and oxygen utilization during dynamic forearm exercise in normal subjects and patients with congestive heart failure. Circulation 1974;50:137-43.
9. Vanhoutte PM. Adjustments in the peripheral circulation in chronic heart failure. Eur Heart J 1983;4(Suppl. A):67-83.
10. Abramson SV, Burke JF, Kelly JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992;116:888-95.
11. Drexler H. Endothelial dysfunction in heart failure and potential for reversal by ACE inhibition. Br Heart J (Suppl) 1994;72:11-14.
12. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enatapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
13. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
14. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasoditatation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918-25.
15. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
16. Katz SD, Krum H, Packer M. Resting and exercise-induced release of endothelium-derived nitric oxide is impaired in patients with heart failure. J Am Coll Cardiol 1994;23:272A(Abstract).
17. Habib F, Dutka D, Crossman D, Oakley C, Cleland JGF. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994;344:371-73.
18. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248:C550-56.
19. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1986;236:339-43.
20. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
21. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci 1993;84:485-500.
22. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
23. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Procl Natl Acad Sci USA 1989;86:2863-67.
24. Howard PG, Plumpton C, Davenport AP. Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992;10:1379-86.
25. Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 1992;90:1023-31.
26. Shinmi O, Kimura S, Sawamura T, et al. Endothelin-3 is a novel neuropeptide: isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem Biophys Res Commun 1989;164:587-93.
27. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.
28. Mumford RA, Pierzchala PA, Strauss AW, Zimmerman M. Purification of a membrane bound metalloendopeptidase from porcine kidney that degrades peptide hormones. Proc Natl Acad Sci USA 1981;78:6623-27.
29. Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharmacol 1994;113:137-42.
30. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990;265:14150-55.
31. Kaufmann H, Oribe E, Oliver JA. Plasma endothelin during upright tilt: relevance for orthostatic hypotension. Lancet 1991;338:1542-45.
32. Fyhrquist F, Saijonmaa O, Metsarrine K, et al. Raised plasma endothelin-1 concentration following cold pressor test. Biochem Biophys Res Commun 1990;169:217-21.
33. Giaid A, Polak JM, Vivekanand G, et al. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung. Am J Respir Cell Mol Biol 1991;4:50-58.
34. Yoshizawa T, Shinmi O, Giaid A, et al. Endothelin: a novel peptide in the posterior pituitary system. Science 1990;247:462-64.
35. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-68.
36. Vierhapper H, Wagner O, Nowotny P, Waldhäusl W. Effects of endothelin-1 in man. Circulation 1990;81:1415-18.
37. Lerman A, Hildebrand FL Jr, Aarhus LL, Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation 1991;83:1808-14.
38. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-33.
39. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990;348:732-35.
40. Simonson MS, Dunn MJ. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J Lab Clin Med 1992;119:622-39.
41. Davenport AP, O'Reilly G, Molenaar P, et al. Human endothelin receptors characterised using reverse transcriptase-polymerase chain reaction, in-situ hybridisation, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 1993;22(Suppl 8):S22-25.
42. de Nucci G, Thomas R, D'Orléans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797-800.
43. Bax WA, Saxena PR. The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci 1994;15:379-86.
44. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993;268:19126-33.
45. Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci 1994;15:9-11.
46. Riezebos J, Watts IS, Vallance PJT. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Phamacol 1994;111:609-15.
47. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994;23:581-86.
48. Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8.
49. White DG, Garratt H, Mundin JW, Sumner MJ, Vallance PJ, Watts IS. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol 1994;257:307-10.
50. Tschudi MR, Lüscher TF. Characterization of contractile endothelin receptors and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 1994;204:685-90.
51. Deng L-Y, Li J-S, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovasc Res 1995;29:532-35.
52. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995;92:357-63.
53. Clarke JG, Benjamin N, Larkin SW, et al. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989;257;H2033-35.
54. Haynes WG, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol 1991;17(Suppl 7):284-86.
55. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989;83:317-20.
56. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-54.
57. Love MP, Haynes WG, Webb DJ, McMurray JJV. Anti-endothelin therapy is of potential benefit in heart failure. Circulation 1994;90:I-547.
58. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282-83.
59. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990;22:839-42.
60. Boarder MR, Marriot DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989;13(Suppl 5):223-24.
61. Cao L, Banks RO. Cardiorenal actions of endothelin, part 1: effects of converting enzyme inhibition. Life Sci 1990;46:577-83.
62. Emori T, Hirata Y, Ohta K, et al. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991;18:165-70.
63. Good JM, Nihoyannopoulos P, Ghatel MA, et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J 1994;15:1634-40.
64. Yang Z, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. Circulation 1990;82:188-95.
65. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992;20:292-97.
66. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-90.
67. Prins BA, Hu R-M, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994;269:11938-44.
68. Saijonmaa O, Ristimäki A, Fyrquist F. Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun 1990;173:514-20.
69. Kohan DE. Endothelins in the kidney: physiology and pathophysiology. Am J Kid Dis 1993;22:493-510.
70. Edwards RM, Trizna W, Ohlstein EH. Renal microvascular effects of endothelin. Am J Physiol 1990;259:F217-21.
71. Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994;46:376-81.
72. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14:385-99.
73. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68:1114-15.
74. McMurray JJ, Ray SG, Abdullah I, Dargie HD, Mortem JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-79.
75. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
76. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC Jr. Increased plasma concentrations of endothelin in chronic heart failure in humans. Mayo Clin Proc 1992;67:719-24.
77. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992;20:849-53.
78. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;26:510-17.
79. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993;71:1293-99.
80. Cacoub P, Dorent R, Nataf P, et al. Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J 1993;126:1484-88.
81. Wei C-M, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-86.
82. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.
83. Cavero PG, Miller WL, Heublein DM, et al. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 1990;259:F312-17.
84. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhäusl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992;22:277-82.
85. Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhäusl W. Regional hemodynamic effects and clearance of endothelin-1 in man: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 1992;14:176-80.
86. Stewart DJ, Levy RD, Cemacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-69.
87. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-65.
88. Löffler BM, Breu V, Clozel M. FEBS Lett 1993;333:108-10.
89. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-36.
90. Momose N, Fukuo K, Morimoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension 1993;21:921-24.
91. Towend J, Doran J, Jones S, Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in chronic heart failure. Int J Cardiol 1994;43:299-304.
92. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardiai infarction. Circulation 1994;89:1573-79.
93. Roubert P, Gillard V, Plas P, Guillon JM, Chabrier PE, Braquet P. Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells. Biochem Biophys Res Commun 1989;164:809-15.
94. Gauquelin G, Thibault G, Garcia R. Renal glomerular endothelin receptors in rats with high-output heart failure. Regulatory Peptides 1991;35:73-79.
95. Löffler B-M, Roux S, Kalina B, Clozel M, Clozel J-P. Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol 1993;25:407-16.
96. Fu L, Sun X, Hedner T, et al. Decreased density of mesenteric arteries but not of myocardiai endothelin receptors and function in rats with chronic ischaemic heart failure. J Cardiovasc Pharmacol 1993;22:177-82.
97. Love MP, Haynes WG, Webb DJ, McMurray JJV. Which endothelin receptors are functionally important in chronic heart failure? Circulation 1995;92:I-331.
98. Teerlink JR, Löffler B-M, Hess P, Maire J-P, Clozel M, Clozel J-P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Circulation 1994;90:2510-18.
99. Ferro CJ, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996;51:12-27.